Analysts Are Bullish on These Healthcare Stocks: Rocket Pharmaceuticals (RCKT), Option Care Health (OPCH)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Rocket Pharmaceuticals (RCKT – Research Report), Option Care Health (OPCH – Research Report) and Incyte (INCY – Research Report) with bullish sentiments.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Rocket Pharmaceuticals (RCKT)
In a report released today, Yun Zhong from Wedbush reiterated a Buy rating on Rocket Pharmaceuticals, with a price target of $16.00. The company’s shares closed last Monday at $4.97.
According to TipRanks.com, Zhong ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Rocket Pharmaceuticals with a $8.38 average price target, representing a 69.3% upside. In a report issued on February 26, LifeSci Capital also maintained a Buy rating on the stock with a $9.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Option Care Health (OPCH)
In a report released today, Lisa Gill from J.P. Morgan maintained a Buy rating on Option Care Health, with a price target of $40.00. The company’s shares closed last Monday at $31.60.
According to TipRanks.com, Gill is a 5-star analyst with an average return of
Currently, the analyst consensus on Option Care Health is a Strong Buy with an average price target of $39.56, a 23.7% upside from current levels. In a report issued on February 25, Morgan Stanley also maintained a Buy rating on the stock with a $38.00 price target.
Incyte (INCY)
In a report released today, Marc Frahm from TD Cowen maintained a Buy rating on Incyte, with a price target of $123.00. The company’s shares closed last Monday at $100.04.
According to TipRanks.com, Frahm is a 5-star analyst with an average return of
Incyte has an analyst consensus of Moderate Buy, with a price target consensus of $109.20, which is a 9.3% upside from current levels. In a report issued on February 18, Barclays also maintained a Buy rating on the stock with a $117.00 price target.
